Procept Biorobotics Corp. (PRCT)
NASDAQ:PRCT
Want to see PRCT full AI Analyst Report?
PRCT Stock Chart & Stats
$25.14
-$0.85(-0.97%)
At close: 4:00 PM EST
$25.14
-$0.85(-0.97%)
Day’s Range― - ―
52-Week Range$19.35 - $66.85
Previous CloseN/A
Volume113.34K
Average Volume (3M)1.51M
Market Cap
$1.50B
Enterprise Value$1.30B
Total Cash (Recent Filing)$245.64M
Total Debt (Recent Filing)$51.66M
Price to Earnings (P/E)―
Beta0.85
Next Earnings
Jul 30, 2026EPS Estimate
-0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.82
Shares Outstanding56,918,842
10 Day Avg. Volume1,413,482
30 Day Avg. Volume1,511,368
Financial Highlights & Ratios
PEG Ratio10.67
Price to Book (P/B)4.78
Price to Sales (P/S)5.67
P/FCF Ratio-29.95
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue4.05
Enterprise Value/Gross Profit6.43
Enterprise Value/Ebitda-12.74
Forecast
1Y Price Target
$33.14Price Target Upside31.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.53
Revenue Forecast (FY)$398.94M
Bulls Say, Bears Say
Bulls Say
Revenue & Procedure GrowthManagement's reiterated FY2026 revenue and procedure targets (27–33% revenue growth; 60k–64k U.S. procedures) signal durable commercial adoption. Consistent procedure volume growth underpins repeatable equipment placements and recurring consumable demand, supporting multi‑period top‑line expansion.
High Gross MarginSustained ~65% gross margins reflect improving unit economics from system and consumable mix. High product margins create structural profitability leverage as volumes scale, making incremental procedure growth highly accretive to operating leverage over the next several quarters.
Recurring Consumable RevenueA strong per‑procedure consumable stream (handpiece ASP growth and high attachment rates) provides predictable, repeatable revenue tied to procedure volume. As installed base and procedure adoption expand, this high‑frequency revenue supports margin stability and recurring cash generation.
Bears Say
Negative Cash FlowPersistent negative operating and free cash flows mean the business remains reliant on external financing or available liquidity to fund growth. Although burn has improved versus prior years, sustained outflows limit financial flexibility and increase refinancing or dilution risk if revenue ramps slip.
High Operating ExpensesRising SG&A and R&D spending are expanding operating losses despite revenue growth. A cost structure that outpaces near‑term revenue can delay sustainable profitability and positive cash flow, making the timing of expense leverage and execution critical to long‑term financial health.
Execution & Timing RiskBenefits from organizational changes, launch teams and pilots are back‑loaded into H2, creating execution risk. If commercial ramp or adoption lags, expected margin and revenue improvements may be delayed, increasing the chance that forecasted EBITDA inflection points slip to later periods.
PROCEPT BioRobotics News
PRCT FAQ
What was Procept Biorobotics Corp.’s price range in the past 12 months?
Procept Biorobotics Corp. lowest stock price was $19.35 and its highest was $66.85 in the past 12 months.
What is Procept Biorobotics Corp.’s market cap?
Procept Biorobotics Corp.’s market cap is $1.50B.
When is Procept Biorobotics Corp.’s upcoming earnings report date?
Procept Biorobotics Corp.’s upcoming earnings report date is Jul 30, 2026 which is in 59 days.
How were Procept Biorobotics Corp.’s earnings last quarter?
Procept Biorobotics Corp. released its earnings results on Apr 29, 2026. The company reported -$0.56 earnings per share for the quarter, beating the consensus estimate of -$0.563 by $0.003.
Is Procept Biorobotics Corp. overvalued?
According to Wall Street analysts Procept Biorobotics Corp.’s price is currently Undervalued.
Does Procept Biorobotics Corp. pay dividends?
Procept Biorobotics Corp. does not currently pay dividends.
What is Procept Biorobotics Corp.’s EPS estimate?
Procept Biorobotics Corp.’s EPS estimate is -0.46.
How many shares outstanding does Procept Biorobotics Corp. have?
Procept Biorobotics Corp. has 56,918,842 shares outstanding.
What happened to Procept Biorobotics Corp.’s price movement after its last earnings report?
Procept Biorobotics Corp. reported an EPS of -$0.56 in its last earnings report, beating expectations of -$0.563. Following the earnings report the stock price went up 10.732%.
Which hedge fund is a major shareholder of Procept Biorobotics Corp.?
Currently, no hedge funds are holding shares in PRCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PROCEPT BioRobotics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$33.14 (31.83% Upside)
$33.14 (31.83% Upside)
Blogger Sentiment
Bullish
PRCT Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 7.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $10.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.9%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.73%
12-Months-Change
Fundamentals
Return on Equity
-27.70%
Trailing 12-Months
Asset Growth
-6.22%
Trailing 12-Months
Company Description
Procept Biorobotics Corp.
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
PRCT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a generally positive operational and commercial trajectory: robust top‑line growth (20% revenue; ~30% procedure growth), margin expansion to management targets (65% gross margin), pricing discipline and meaningful clinical/regulatory wins (EAU guideline upgrade, FDA clearance). These positives are balanced against higher operating expenses, larger GAAP and adjusted EBITDA losses in Q1, tariff headwinds and short‑term disruption from a commercial realignment that push some benefits into the back half of 2026. Management reaffirmed full‑year guidance while taking a prudent near‑term stance, expecting improved leverage and positive EBITDA in Q4.View all PRCT earnings summariesPRCT Stock 12 Month Forecast
Average Price Target
$33.14
▲(31.83% Upside)
Technical Analysis
Alphatec Holdings
―
Artivion
―
LivaNova
―
Inspire Medical Systems
―
SS Innovations International
―
Ownership Overview
3.78% Insiders
27.77% Mutual Funds
39.57% Other Institutional Investors
14.06% Public Companies and
Individual Investors